Neurocrine Biosciences
NBIX
174 hedge funds and large institutions have $3.38B invested in Neurocrine Biosciences in 2015 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 13 closing their positions.
331% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 13
101% more capital invested
Capital invested by funds: $1.68B → $3.38B (+$1.7B)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
46% more call options, than puts
Call options by funds: $32.5M | Put options by funds: $22.3M
31% more funds holding
Funds holding: 133 → 174 (+41)
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$81.9M |
| 2 |
PC
PointState Capital
New York
|
+$67.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$60.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.6M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$46.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$26M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$25.5M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$20.4M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$17.9M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$15.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GH
176
GAM Holding
Zurich,
Switzerland
| – | -$2.23M | -100,000 | Closed |
|
|
MLICM
177
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$1.28M | -57,136 | Closed |
|
|
GPCM
178
Granite Point Capital Management
Boston,
Massachusetts
| – | -$894K | -40,000 | Closed |
|
179
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$967K | -27,043 | Closed |
|
|
TI
180
Trexquant Investment
Stamford,
Connecticut
| – | -$572K | -25,622 | Closed |
|
|
ST
181
Spot Trading
Chicago,
Illinois
| – | -$363K | -16,231 | Closed |
|
|
FMT
182
First Mercantile Trust
Cordova,
Tennessee
| – | -$286K | -12,800 | Closed |
|
|
HCM
183
Highbridge Capital Management
New York
| – | -$430K | -12,016 | Closed |
|
|
PAG
184
Private Advisor Group
Morristown,
New Jersey
| – | -$251K | -11,238 | Closed |
|
185
Simplex Trading
Chicago,
Illinois
| – | -$378K | -10,573 | Closed |
|
186
Bessemer Group
Woodbridge,
New Jersey
| – | -$34K | -1,500 | Closed |
|
|
RC
187
RegentAtlantic Capital
Morristown,
New Jersey
| – | -$2.23K | -100 | Closed |
|
NBIX Hedge Fund Activity: Q1 2015 in Review
174 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2015, worth a combined $3.38B — up 101% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new NBIX positions and 13 closed out — a net gain of 43 holders — while 56 added to existing stakes and 55 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $81.9M. The largest seller was Citadel Advisors, cutting an estimated $26M.
- 174 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2015, up from 133 in Q4 2014.
- Funds reported $3.38B of Neurocrine Biosciences stock for Q1 2015, up 101% quarter-over-quarter.
- 56 funds opened new Neurocrine Biosciences positions in Q1 2015 and 13 closed out, a net change of +43 holders.
- The largest Neurocrine Biosciences buyer in Q1 2015 was Westfield Capital Management, an estimated $81.9M added.
- The largest Neurocrine Biosciences seller in Q1 2015 was Citadel Advisors, an estimated $26M sold.
Based on aggregated 13F filings for Q1 2015.